Interim vaccine effectiveness against influenza virus among outpatients, France, October 2025 to January 2026

In Europe, the 2025/26 seasonal influenza epidemic started in October 2025. Co-circulation of A(H3N2) and A(H1N1)pdm09 was observed in several countries including France. We estimated early vaccine effectiveness (VE) against influenza virus in French outpatients (5,451 positives/18,816 negatives). A significant VE across all age groups was measured: 28% (95% CI: 17-37) for those aged ≥ 65 years, 45% (95% CI: 36-53) for 18-64-year-olds and 57% (95% CIs: 29-74) for 0-17-year-olds. Reinforcing vaccination uptake is warranted.

Authors

Institutions

Publication Details

Journal
Eurosurveillance
Published
2026-01-15
DOI
https://doi.org/10.2807/1560-7917.es.2026.31.2.2500992
Citations
6
Primary Topic
Influenza Virus Research Studies
Type
article
Field-Weighted Citation Impact
189.13
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Interim vaccine effectiveness against influenza virus among outpatients, France, October 2025 to January 2026

Thomas Duret, Alexandra Jacques, Vincent Vieillefond, Danielle Perez-Bercoff et al.
6 citations
Eurosurveillance
Influenza Virus Research Studies
189.13
article

Interim vaccine effectiveness against influenza virus among outpatients, France, October 2025 to January 2026

Thomas Duret, Alexandra Jacques, Vincent Vieillefond, Danielle Perez-Bercoff, Stéphanie Haïm‐Boukobza, Benoit Visseaux, Marie Anne Rameix-Welti, Lina Bruno, Guillaume Deleglise, Valentin Wehrle, Antonin Bal, Sibylle Bernard-Stoecklin, Laurence Josset, on behalf of the RELAB study group, Antoine Oblette, François Blanquart, Allan De Clercq
article en
6 citations

Abstract

In Europe, the 2025/26 seasonal influenza epidemic started in October 2025. Co-circulation of A(H3N2) and A(H1N1)pdm09 was observed in several countries including France. We estimated early vaccine effectiveness (VE) against influenza virus in French outpatients (5,451 positives/18,816 negatives). A significant VE across all age groups was measured: 28% (95% CI: 17-37) for those aged ≥ 65 years, 45% (95% CI: 36-53) for 18-64-year-olds and 57% (95% CIs: 29-74) for 0-17-year-olds. Reinforcing vaccination uptake is warranted.

EurosurveillanceVol. 31(2)
Université Claude Bernard Lyon 1 (FR), Georgia Tech Lorraine (FR), Centre National de la Recherche Scientifique (FR), Inserm (FR), Institut Pasteur (FR), Collège de France (FR), Université de Versailles Saint-Quentin-en-Yvelines (FR), Université Paris Cité (FR), Université de Lille (FR), Université Paris Sciences et Lettres (FR), RCVS Knowledge (GB), Santé Publique France (FR), Hospices Civils de Lyon (FR), Honeywell (France) (FR), Centre Interdisciplinaire de Recherche en Biologie (FR), Centre Hospitalier Universitaire de Clermont-Ferrand (FR), Centre International de Recherche en Infectiologie (FR), Houillères de Lorraine (FR), Infection et inflammation (FR), Virbac (France) (FR)
Good health and well-being
Openalex Percentile: Top 0%
Influenza Virus Research Studies
189.13
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.